Development of a nomogram for overall survival in patients with esophageal carcinoma: A prospective cohort study in China

doi:10.4251/wjgo.v17.i1.96686

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (374)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

HTML

177

Figures (1-5)

Tables (1-2)

Sum=296

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=67

Jan 15, 2025 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96686
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96686

Table 1 Patient demographics and clinical characteristics

Characteristics	Overall (n = 3127)	Training cohort (n = 2189)	Validation cohort (n = 938)	P value
Age¹	65.30 ± 8.59	65.35 ± 8.65	65.19 ± 8.46	0.620
KPS¹	83.75 ± 8.11	83.74 ± 7.97	83.78 ± 8.43	0.910
Sex, n (%)
Male	2549 (81.52)	1789 (81.73)	760 (81.02)	0.679
Female	578 (18.48)	400 (18.27)	178 (18.98)
BMI, n (%)
18.5-23.9	1931 (61.75)	1350 (61.67)	581 (61.94)	0.357
≥ 24	720 (23.03)	494 (22.57)	226 (24.09)
< 18.5	476 (15.22)	345 (15.76)	131 (13.97)
Base disease, n (%)
No	2521 (80.62)	1757 (80.26)	764 (81.45)	0.472
Yes	606 (19.38)	432 (19.74)	174 (18.55)
Pathological, n (%)
SCC	3021 (96.61)	2121 (96.89)	900 (95.95)	0.219
Others	106 (3.39)	68 (3.11)	38 (4.05)
TNM, n (%)
I	226 (7.23)	162 (7.40)	64 (6.82)	0.703
II	780 (24.94)	536 (24.49)	244 (26.01)
III	1230 (39.33)	858 (39.20)	372 (39.66)
IV	891 (28.49)	633 (28.92)	258 (27.51)
Radiotherapy, n (%)
No	1918 (61.34)	1345 (61.44)	573 (61.09)	0.883
Yes	1209 (38.66)	844 (38.56)	365 (38.91)
Chemotherapy, n (%)
No	1804 (57.69)	1265 (57.79)	539 (57.46)	0.897
Yes	1323 (42.31)	924 (42.21)	399 (42.54)
Surgery, n (%)
No	1644 (52.57)	1156 (52.81)	488 (52.03)	0.716
Yes	1483 (47.43)	1033 (47.19)	450 (47.97)
Immunotherapy, n (%)
No	2901 (92.77)	2029 (92.69)	872 (92.96)	0.846
Yes	226 (7.23)	160 (7.31)	66 (7.04)
Targeted, n (%)
No	3019 (96.55)	2117 (96.71)	902 (96.16)	0.507
Yes	108 (3.45)	72 (3.29)	36 (3.84)
LDH¹	202.19 ± 155.15	202.47 ± 143.90	201.53 ± 178.76	0.877
β2. Microglobulin¹	2.59 ± 1.19	2.58 ± 1.15	2.61 ± 1.28	0.472
CD4/CD8¹	1.81 ± 1.06	1.80 ± 1.05	1.85 ± 1.09	0.163
ALB/GLB¹	1.37 ± 0.32	1.37 ± 0.31	1.38 ± 0.32	0.707
PLR¹	168.66 ± 113.61	168.01 ± 111.13	170.17 ± 119.24	0.625
LMR²	3.33 [2.36, 4.65]	3.32 [2.36, 4.61]	3.37 [2.41, 4.79]	0.147
NLR²	2.74 [1.94, 4.09]	2.74 [1.92, 4.12]	2.74 [1.97, 4.02]	0.714

¹Expressed as mean ± SD.

²Expressed as median[P25, P75].

PLR: Platelet-to-lymphocyte ratio; BMI: Body mass index; KPS: Karnofsky performance status; LDH: Lactic dehydrogenase; SCC: Esophageal squamous cell carcinoma; LMR: Lymphocyte-monocyte ratio; NLR: Neutrophil-lymphocyte ratio.

Citation: Yu SS, Zheng X, Li XS, Xu QJ, Zhang W, Liao ZL, Lei HK. Development of a nomogram for overall survival in patients with esophageal carcinoma: A prospective cohort study in China. World J Gastrointest Oncol 2025; 17(1): 96686
URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96686.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96686